Tesamorelin (TH9507) | Peptide Reference Material
RESEARCH PEPTIDE

Tesamorelin (TH9507) | Peptide Reference Material

Stabilized GHRH Analogue — Research Peptide
$39.00
Stabilized growth-hormone-releasing-hormone analogue supplied as a lyophilized laboratory reference material for receptor and GH-axis research. Research use only. Not for human or veterinary use.
✓ Identity Verified
✓ Batch Documentation
✓ QR Lot Verification
✓ Research Use Only
✓ U.S. Fulfillment
✓ Batch Verification Available View verification →
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
218949-48-5
Purity
≥98%
Molecular Formula
C221H366N72O67S
Molecular Weight
5135.7
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

Tesamorelin (TH9507; CAS 218949-48-5) is a 44-residue GHRH analogue bearing an N-terminal trans-3-hexenoyl group, supplied as a laboratory reference material. Research use only.

Primary Research Category
Growth Hormone Research
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Growth Hormone Axis Endocrine Research Hormonal Regulation Body Composition

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

Tesamorelin acts as a GHRH-receptor agonist: non-clinical pharmacology characterized TH9507 as a stabilized GHRH analogue that stimulates growth hormone secretion through the GHRH receptor pathway, with downstream elevation of IGF-1 observed in the referenced literature (Ferdinandi et al., 2007). Mechanistic attribution in this dossier is limited to the receptor-agonist pharmacology characterized in these studies.

Primary Organ Systems
  • Endocrine System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

Batch Verified
Independent Batch Verification

Independent laboratory verification for this batch:

  • Identity Confirmation
  • HPLC Purity Analysis
  • Net Peptide Content
  • Endotoxin Testing
  • Analytical Chromatogram
  • Independent Laboratory Verification
View Batch Verification →
Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Pharmacology Study•Basic & Clinical Pharmacology & Toxicology• 2007

Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

Non-clinical pharmacology and safety evaluation characterizing TH9507 (tesamorelin) as a stabilized human growth hormone-releasing factor analogue, including its GHRH-receptor-mediated stimulation of the growth hormone axis.
Velora Research Insight
Foundational pharmacology anchor for the dossier's mechanism treatment; characterizes the analogue itself rather than clinical outcomes.
PubMed →DOI →
Clinical Trial•The New England Journal of Medicine• 2007

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Randomized controlled trial reporting metabolic effects of the growth hormone-releasing factor analogue tesamorelin, including reduction of visceral adipose tissue, in HIV-infected patients with abdominal fat accumulation.
Velora Research Insight
Primary clinical research context for the growth-hormone-axis pharmacology of tesamorelin; cited as scientific context, not as a therapeutic representation of this material.
PubMed →DOI →
Clinical Trial•JAMA• 2014

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

Randomized clinical trial examining the effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation.
Velora Research Insight
Extends the clinical research context to hepatic/visceral fat endpoints relevant to body-composition research; context only, no therapeutic representation.
PubMed →DOI →
Review Article•Drugs• 2011

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

Review synthesizing the pharmacology and clinical study literature for tesamorelin, the stabilized growth hormone-releasing factor analogue.
Velora Research Insight
Consolidated evidence synthesis bridging the analogue's receptor pharmacology and the clinical research context.
PubMed →DOI →